ReviewCureus2022
Biomarkers of Neonatal Sepsis: From Being Mere Numbers to Becoming Guiding Diagnostics.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of interleukin-6 (IL-6) as a significant biomarker in late-onset neonatal sepsis: an updated systematic review and meta-analysis.European journal of pediatrics · 2025Pooled it
- Aligning neonatal sepsis triage diagnostics with WHO target product profiles in low- and middle-income countries.BMJ global health · 2026Review
- Potential Health and Cost Impacts of a Point-of-Care Test for Neonatal Sepsis and Possible Serious Bacterial Infections in Infants: A Modeling Analysis in Two Settings.Open forum infectious diseases · 2025Article
- Predicting Neonatal Morbidity and Correlations with Maternal and Neonatal Biomarkers in Connection with Fetal Inflammatory Response Syndrome in Premature Births.Journal of clinical medicine · 2025Article
- C-reactive Protein Versus Procalcitonin in the Early Diagnosis of Neonatal Sepsis: A Systematic Review.Cureus · 2025Review
- Biomarker-guided antibiotic stewardship in neonatology: time for implementation?Pediatric research · 2025Article
- Serum Biomarkers in Patent Ductus Arteriosus in Preterm Infants: A Narrative Review.Biomedicines · 2025Review
- Use and utility of C-reactive protein (CRP) in neonatal early-onset sepsis: a secondary analysis of a prospective surveillance study.Journal of perinatology : official journal of the California Perinatal Association · 2025Observational
- Umbilical cord blood level of interleukins used as a predictor of early-onset neonatal sepsis: a comprehensive review.Frontiers in cellular and infection microbiology · 2025Review
- Crossing Age Boundaries: The Unifying Potential of Presepsin in Sepsis Diagnosis Across Diverse Age Groups.Journal of clinical medicine · 2024Review
- Neonatal Infectious Disease: A Major Contributor to Infant Mortality Requiring Advances in Point-of-Care Diagnosis.Antibiotics (Basel, Switzerland) · 2024Review
- Predictive Role of Maternal Laboratory Parameters and Inflammatory Scores in Determining Systemic Inflammatory Response Syndrome in Newborns at Birth.Journal of personalized medicine · 2024Article
- Laboratory markers to identify acute histological chorioamnionitis in febrile parturients undergoing epidural analgesia: a retrospective study.BMC pregnancy and childbirth · 2023Article
- Early Diagnostic Markers of Late-Onset Neonatal Sepsis.Pediatric reports · 2023Article
- Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going.Antibiotics (Basel, Switzerland) · 2023Review
- Group BAntibiotics (Basel, Switzerland) · 2023Review
- Release of HMGB1 and Toll-like Receptors 2, 4, and 9 Signaling Are Modulated byInternational journal of molecular sciences · 2023Article
- A Prospective, Case-Control Study of Serum Metabolomics in Neonates with Late-Onset Sepsis and Necrotizing Enterocolitis.Journal of clinical medicine · 2022Article
- Antibiotic Stewardship Quality Improvement Project for Neonatal Sepsis in a Tertiary NICU in Lima, Peru.Pediatric quality & safetyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal sepsis is a common cause of neonatal morbidity and mortality. The diagnosis of newborn sepsis is still difficult. Different early objective diagnostic tests or specific signs and symptoms, particularly in preterm infants, make it difficult to diagnose neonatal sepsis. This review article describes biomarkers and their role in the early diagnosis, treatment, and prognosis of neonatal sepsis. It also explores the possible advances and future prospects of these biomarkers. An ideal sepsis biomarker will not only help in the guidance of the use of antibiotics when not needed but also the duration of the course of antibiotics if sepsis is proven. It should also have high sensitivity, specificity, positive predictive value, and negative predictive value. These biomarkers hold a promising position in the management of neonatal sepsis and translate into use in clinical settings. Metabolomics, a diagnostic method based on detecting metabolites found in biological fluids, may open new possibilities in the management of critically ill newborns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.